34945-66-9

Usage

Uses

Used in Pharmaceutical Industry:
3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-7-carbonitrile is used as a building block for the synthesis of various pharmaceuticals. Its unique chemical structure and properties allow it to be incorporated into the development of drugs with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical industry, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-7-carbonitrile is utilized as a key intermediate in the production of herbicides and insecticides. Its incorporation into these products can enhance their effectiveness in controlling pests and unwanted plant growth.
Used in Organic Synthesis:
3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-7-carbonitrile is also used as a versatile intermediate in organic synthesis. Its chemical structure allows for further modification and functionalization, making it a valuable component in the creation of new and innovative compounds for various applications.

Upstream product

• 544-92-3 copper(I) cyanide 
• 34950-82-8 7-bromo-3,4-dihydro-2H-pyrido[3,2-β][1,4]oxazine 
• 20348-23-6 3,4-dihydro-2H-pyrido[3,2-b ][1,4]oxazine 
• 31354-48-0 N-(3-hydroxypyridin-2-yl)acetamide 
• 89970-14-9 1-(2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)ethyl ketone 
• 16867-03-1 2-amino-3-hydroxypyridine 
• 566158-30-3 1-(7-bromo-2H-pyrido[3,2-b][1,4]oxazin-4 (3H)-yl)ethyl ketone 
• 557-21-1 dicyanozinc 

Relevant academic research and scientific papers

An expedient Pd/DBU mediated cyanation of aryl/heteroaryl bromides with K4[Fe(CN)6]

A practical Pd(PPh3)4/DBU catalytic system for the synthesis of pharmaceutically relevant aminopyridine nitrile intermediates, as well as a variety of other aryl nitriles using non-toxic K4[Fe(CN) 6] has been developed. The key features of our new protocol for cyanation lie in that the reaction can be carried out with readily available Pd(PPh3)4 under mild and green conditions, even without the assistance of other ligands. The Royal Society of Chemistry 2012.

Acridone-based inhibitors of inosine 5′-monophosphate dehydrogenase: Discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1- yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419)

Inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides, catalyzes the irreversible nicotinamide-adenine dinucleotide dependent oxidation of inosine-5′- monophosphate to xanthosine-5′-monophosphate. Mycophenolate Mofetil (MMF), a prodrug of mycophenolic acid, has clinical utility for the treatment of transplant rejection based on its inhibition of IMPDH. The overall clinical benefit of MMF is limited by what is generally believed to be compound-based, dose-limiting gastrointestinal (GI) toxicity that is related to its specific pharmacokinetic characteristics. Thus, development of an IMPDH inhibitor with a novel structure and a different pharmacokinetic profile may reduce the likelihood of GI toxicity and allow for increased efficacy. This article will detail the discovery and SAR leading to a novel and potent acridone-based IMPDH inhibitor 4m and its efficacy and GI tolerability when administered orally in a rat adjuvant arthritis model.